User:ImpLake/sandbox/1
From Wikipedia, the free encyclopedia
The Moderna COVID‑19 vaccine (pINN: elasomeran[14]), codenamed mRNA-1273 and sold under the brand name Spikevax,[2] is a COVID-19 vaccine developed by Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA). It is authorized for use in people aged 12 years and older in some jurisdictions and for people 18 years and older in other jurisdictions to provide protection against COVID-19 which is caused by infection by the SARS-CoV-2 virus.[10][2] It is designed to be administered as two 0.5 mL doses given by intramuscular injection at an interval of 29 days apart.[15]
![]() Vials of the Moderna COVID-19 vaccine | |
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Pronunciation | /məˈdɜːrnə/ mə-DUR-nə[1] |
Trade names | Spikevax[2] |
Other names | mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection,[3] |
AHFS/Drugs.com | Multum Consumer Information |
MedlinePlus | a621002 |
License data | |
Routes of administration | Intramuscular |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG |
It is an RNA vaccine composed of nucleoside-modified mRNA (modRNA) encoding a spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles.[16]
The Moderna COVID‑19 vaccine is authorized for use at some level in 53 countries, including Canada, European Economic Area countries, Singapore, Philippines, South Korea, Thailand, the United Kingdom, and the United States.[17]
On 15 March 2021, Moderna's second COVID‑19 vaccine (mRNA-1283) started phase I clinical trials.[18][19]